Drug Profile
Paclitaxel polymeric micelle formulation - Samyang
Alternative Names: Cremophor EL-free polymeric micelle of paclitaxel; Cynviloq; Genexol-PM; Genexsol; IG-001; NANT-008; Nant-paclitaxel; paclitaxel loaded polymeric micelle - SamyangLatest Information Update: 10 Apr 2024
Price :
$50
*
At a glance
- Originator Samyang Biopharmaceuticals Corporation; Samyang Group
- Developer Boryung Pharmaceutical; NantPharma; Samyang Biopharmaceuticals Corporation; Samyang Group; Sorrento Therapeutics
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Breast cancer; Non-small cell lung cancer; Ovarian cancer
- Phase II Bladder cancer; Pancreatic cancer
- Phase I/II Gastric cancer
- No development reported Gynaecological cancer
Most Recent Events
- 06 Dec 2023 NantPharma withdraws a phase Ib/II trial in Pancreatic cancer (First-line therapy, Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unrespectable) in USA (IV) prior to enrolment (NCT03127124)
- 02 Dec 2023 Samyang Biopharm and Boryung Pharmaceutical completes a phase-I/II trial in Gastric cancer (Late-stage disease) in South Korea (Intraperitoneal) (NCT03618758)
- 02 Jun 2023 Adverse events and efficacy data from a phase II trial in Pancreatic cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)